Form 4: PepGen Inc. CFO Donnelly Receives Stock Options
SEC Form 4 Filing
Noel Donnelly, CFO of PepGen Inc., was granted stock options to purchase 144,000 shares of common stock.
Summary
- On March 1, 2024, Noel Donnelly, the Chief Financial Officer of PepGen Inc., received stock options.
- These options grant him the right to purchase 144,000 shares of PepGen's common stock at an exercise price of $16.62 per share.
- The options vest over a period of four years, with 25% vesting on the one-year anniversary of the grant date (March 1, 2025) and the remaining 75% vesting in 36 equal monthly installments thereafter, contingent upon continued service with the company.
- The options expire on February 28, 2034.
Sentiment
Score: 7
Explanation: The document reflects a standard executive compensation practice, which is generally viewed neutrally to positively as it aligns management incentives with shareholder value. The sentiment is moderately positive due to the incentive structure.
Positives
- The granting of stock options to the CFO aligns his interests with those of the shareholders, incentivizing him to work towards the company's success.
- The vesting schedule encourages long-term commitment from the CFO.
Industry Context
Stock options are a common form of executive compensation in the biotechnology industry, used to attract and retain talent and align management's interests with those of shareholders.
Comparison to Industry Standards
- Stock option grants are a standard component of executive compensation packages in the biotech industry.
- Companies like BioMarin Pharmaceutical and Sarepta Therapeutics also utilize stock options as part of their executive compensation plans.
- The vesting schedule and exercise price are typical for similar grants in the industry, designed to incentivize long-term performance.
Stakeholder Impact
- Shareholders may view the granting of stock options positively as it incentivizes the CFO to improve company performance.
- Employees may see this as a positive sign of the company's commitment to its leadership.
Key Dates
| Date | Description |
|---|---|
| 03/01/2024 | Date of the transaction (grant date of stock options) |
| 03/01/2025 | First vesting date (25% of options) |
| 02/28/2034 | Expiration date of the stock options |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.